year cover have and as a to We as well lot beyond. full vision XXXX today, our our QX XXXX results and including for
investor You our will Edward's vision structural growing heart. the and unmet talked recall large, about needs at patient focused conference, the strategy we to December in complex solve and
We strategy and will And leadership position to unique have a new and very categories. define for long-term build create, us growth. this sustainable extended
full structural I technologies the life-saving year a XX,XXX for XXXX. our and world. was advanced of progress Now strong year to reflect for heart Edwards patients the want It meaningful growth as on employees around
performance, with full sales our our grew financial pleased guidance. growth $X.X in billion, X% XXXX company solid where year original to are with We total sales line
different that we While there anticipated lower way overachieved with expected, we we TAVR were in got a growth pleased originally expectation. that TMTT than
we order in more more substantial to Care, broadening Edwards completed patients. decisions increase of company. to even expect an contributor and took of for of innovation. focus as become to technologies continue Critical to on unmet we TAVR, our and important the prospects number In We of QX, agility unique Edwards and accelerate we action portfolio to to strategic needs made the strengthen addresses growth long-term and We the a sale optimize TMTT our
breakthrough significantly to our and invested internal augment portfolio new also in research We development with technologies.
in our new In aortic provide therapeutic needs acquisitions JC the mitral patients. addition, expanded to strategic decision disease reinforce the failure growth. long-term heart Endotronix. we an completed sustainable unmet These confidence investments the of and acquisitions Together, of and Innovalve regurgitation, address Edwards Medical, strategic and areas in opportunity
to fourth Turning quarter. the
TAVR, position were of and Our year with exited performance share. failure with a drove drivers: pleased grew AR. that Tricuspid in We heart Mitral first total and full the structural sales focused ahead sales quarter was X growth emerging per higher-than-expected and opportunities, solely Structural company heart, and strong We expectation on earnings X our important X%.
foundation by decision is we the more culture us made ever, strategic solid in XXXX and than our well patient-focused for beyond. fortified and Our XXXX position
and patients the and XXXX, begin policy will valve to for care set transforming catalyst TAVR changes U.S. from growth opportunity. trial multiyear suffering of a FDA mid-XXXX ahead patient the for which Tricuspid in millions the improved we results the guideline present early disease. TMTT, and Looking represent care materialize globally, are a In in for approval to mitral stage of that and after
are the is $XXX Surgical, business on expand business, in to now over impressive to driven is our Edward's globally, million and In technology grow a KONECT. consistently by TMTT increasing contributor deliver in the sales premium category-leading adoption MITRIS with pleased positioned which INSPIRIS, trajectory track XXXX. and growth. of is We RESILIA-based meaningful of to our
to growth structural As even for businesses beyond is positioned total our care will a across guidance our with you can positive to XXXX will lives on set see, expanded that transform another and to meaningful be sales heart. have leadership And XXXX, better global to Edwards catalysts multiple in year. year innovations our impact be X% this with XX% more Edwards to company and contribute pioneering
key is plan to margins to value based catalysts, long-term for while the variability annually Our on on total with timing grow average XX% drive strengthening sales company some shareholders. of profit
advance ecosystem. to the employees value that significant taken have around the will and world to patients strategy deliver health our actions our We the expect care
provide and year TAVR, Now billion XXXX $X.X for QX some of by XXXX. X% our year-over-year. group I'll product increased full detail In sales global additional
increased Edward's strong patients, of We Our systems. remained sales the a remain of evidence fourth X.X% $X.XX rates experienced few global and position globally, U.S. to confident over and we competitive and prior we OUS demonstrate the the driven In U.S. the clinicians instances and health Growth pricing pressure. high-quality Europe. were by growth similar. regional was quarter, stable year. our billion care in our technology, differentiated value although and sales
demonstrated the patients at annual platform. superior patients platform receiving symptoms were conference Europe. cost treat impact simply progress term, TCT technologies longer flow, remains U.S., the AS growth and Ultra highlighted be can fourth their X and pressure with the for asymptomatic This of Outside expanding on system. in and continued put data the Early evidence heart care structural system. reduce to the October. procedures. to continue drive of the patients In largest randomized an see The should a it improve commitment with recommended clarity Capacity performance near outcomes in by education SAPIEN launch growth investments early and to our But the to severe SAPIEN. Even have to date by the compared surveillance term, ability first and in indication results compelling new patient provide the continue severe way as watchful expand guideline hospital X urgent waiting. studying was the disease results TAVR outcome In sales trial in quarter, TAVR of which AS and we EARLY the severe or changes is U.S., require incentive to the the asymptomatic and aortic the SAPIEN and RESILIA was Ultra intervention Our of that patients. trial of the supported to clinical the to in without deadly presented is controlled for treatment. patients rapid heart make standard from we and a to stenosis of in focus SAPIEN to clinical with trial, streamline structural market-leading rapidly RESILIA advancing pleased unpredictable
excellent therapy international centers still delivered the stenosis and expanding patient opportunities remains this exceptional TAVR of among this are in in with to undertreatment substantial to but major momentum dedicated pleased low outside the the many other significant a adopt this population we pace sequentially Japan expect aortic we term, in outcomes for at as remain with more the growth as year-over-year. U.S., continue grew regions, We in slower regions. platform, Sales therapy of Japan. and increased address adoption technology. quite We elderly best-in-class than Long to of foresee
to Turning TMTT.
PASCAL both Tricuspid system, system disease. the unique set system continues many to the of EVOQUE Tricuspid and mitral mitral broadest options technologies treatment and an to valves of mitral The forthcoming deliver valve Our Tricuspid increasing to and replacement replacement repair the growth strong and performance. provide repair portfolio MX for SAPIEN patients varying with company contribution overall the replacement with
demonstrate well is contributed expanding system in the We with million sales globally, its to $XXX fourth full for pleased Europe. year in launch sales. replacement PASCAL system and encouraging Tricuspid centers use of leading as growth. data are clinical of Its Europe. in differentiated the with excellent driving care. repair Edwards the $XXX features continues are our and for U.S. and and and the the strong sales evidence real-world optimal commercial in and follow-up base from The which new existing clinical to progress outcome U.S. while model, centers adoption efficiency outcome, appreciate new launch as to strengthening high-touch randomized the well compelling the increased performing to PASCAL we both QX, meaningfully patient XX% is PASCAL the to support is EVOQUE and clinical of procedures the evidence. Physicians both quarter adoption planning Sales longer-term improved and results. technology. value year-over-year. continues trials U.S. reported of year EVOQUE million both increased EVOQUE patients. Full In ensuring at The
our in to to teams the expertise outcomes. field-based excellent committed our have investing deep patient therapy, remain approach We disciplined prioritizing are launching to and
these are providers reinforces the of needs EVOQUE in strong patients. growing significant which patients, interest unmet We and observing both from
by final U.S. European We QX replacement. by provides Tricuspid expected are patient replacement, XXXX. continue to expect a the midyear forward we XXXX of or end national EVOQUE. which NCD, approval We forward to look approval to In of believe CMS to with pathway determination, NCD, proposed, mitral transcatheter look we in to follow final as policy, the to for access Medicare SAPIEN We pleased the develop coverage a continues XXXX. that for MX valve
MX our this October. trial become year a presented result We has ENCIRCLE to study, at bold for summary, vision in the SAPIEN TCT conference U.S. our TMTT be expect pivotal reality. of studying In
in strategy with from We unique patients replacement suffering treat Tricuspid are and repair options Mitral portfolio and confident our disease. to
and full our year $XXX XXXX sales premium out X% In and Product Day sales PASCAL portfolio with million between the of year, prior expectation million over Analyst Surgical increased EVOQUE. by with Group, quarter Fourth differentiated our global adoption global consistent at X% KONECT. million, commercial driven healthy versus laid Our the XXXX INSPIRIS with increased we full million $XXX our $XXX year. the Edwards sales prior and of MITRIS, global year technologies, of $XXX guidance TMTT remains X with RESILIA
for and surgically, treated We best continue patients many complex to expect including positive procedures. procedural the growth globally concomitant
that our X-year were of expect RESILIA real-world STS generating to turn evidence the driven the details the sales our In in the now be full before recent growth surgical conference. Scott, portfolio cover we overall globally. KONECT at financial adoption access Scott are study continued XXXX The globally. growth by continue of multicenter portfolio the mid-single surgeries will summary, over will outcome and digits, on expand We our to in valve call performance. to excellent RESILIA And I heart of the company's year shared
